Skip to content
0032-spray

AdaptDx Disinfecting Recommendations

The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.

ClaudioLagunas Claudio Lagunas, OD View all testimonials

For Practices

Subclinical AMD Detection

Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.

For Patients

Protect Your Eyesight

Talking to your eye doctor about risk factors or trouble seeing at night may help detect macular degeneration early enough to hopefully delay progression of disease.

Breakthrough Technology Meets High-Touch Patient Care

Measuring dark adaptation speed with the AdaptDx Pro® can be useful in diagnosing AMD at the subclinical stage and managing this progressive disease with the hope of preventing unnecessary vision loss.

The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.

RyanPowell Ryan Powell, OD View all testimonials

Latest News & Upcoming Events

View More
Article: February 17, 2021 | Good Day PA

Talking All About Passionate Eye Care with Kirman Eye

In a special Good Day PA segment, an interviewer connected with Dr. Gary Kirman on the importance of optimal care when it comes to eye health, particularly with regard to AMD.

Our Blog: February 4, 2021

Two Birds, One Stone

Testing dark adaptation speed for every patient over 50 allows eye care professionals prioritize both patients and practice. By Tammy Tully, OD.

Article: December 30, 2020 | Review of Optometric Business

Treatment Plan & Technology Investment Generating More than $65,000 Annually

Victoria Dzurinko, OD, MBA, FAAO, discusses the opportunity available to improve both patient outcomes and practice bottom lines by integrating dark adaptation testing in the identification and management of AMD.